30.61
전일 마감가:
$30.25
열려 있는:
$30.25
하루 거래량:
1.75M
Relative Volume:
1.04
시가총액:
$5.05B
수익:
$1.51B
순이익/손실:
$333.35M
주가수익비율:
15.70
EPS:
1.95
순현금흐름:
$315.22M
1주 성능:
+4.29%
1개월 성능:
+6.40%
6개월 성능:
+5.48%
1년 성능:
+31.88%
Alkermes Plc Stock (ALKS) Company Profile
명칭
Alkermes Plc
전화
00-353-1-772-8000
주소
CONNAUGHT HOUSE, DUBLIN 4
ALKS을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ALKS
Alkermes Plc
|
30.61 | 4.84B | 1.51B | 333.35M | 315.22M | 1.95 |
![]()
HLN
Haleon Plc Adr
|
11.35 | 50.14B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
ZTS
Zoetis Inc
|
168.63 | 72.38B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
RDHL
Redhill Biopharma Ltd Adr
|
1.79 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 45.51B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.78 | 19.45B | 16.54B | -1.64B | 749.00M | -1.45 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-05-28 | 개시 | Needham | Buy |
2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
2025-03-04 | 업그레이드 | UBS | Sell → Neutral |
2025-02-11 | 개시 | Deutsche Bank | Buy |
2024-11-05 | 업그레이드 | Stifel | Hold → Buy |
2024-06-17 | 개시 | TD Cowen | Buy |
2024-03-19 | 개시 | Robert W. Baird | Outperform |
2024-02-20 | 다운그레이드 | UBS | Neutral → Sell |
2023-11-20 | 재개 | JP Morgan | Neutral |
2023-10-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
2023-10-17 | 개시 | UBS | Neutral |
2022-11-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2022-10-14 | 업그레이드 | BofA Securities | Underperform → Neutral |
2022-08-16 | 개시 | Piper Sandler | Neutral |
2022-04-22 | 재개 | Goldman | Buy |
2022-04-20 | 개시 | Goldman | Buy |
2022-01-27 | 업그레이드 | Cantor Fitzgerald | Hold → Overweight |
2021-12-01 | 개시 | Citigroup | Neutral |
2021-10-07 | 업그레이드 | Jefferies | Hold → Buy |
2021-09-02 | 다운그레이드 | BofA Securities | Neutral → Underperform |
2020-10-15 | 업그레이드 | Mizuho | Neutral → Buy |
2020-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
2020-02-14 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
2020-02-14 | 재확인 | H.C. Wainwright | Neutral |
2020-02-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2020-02-06 | 개시 | Mizuho | Neutral |
2020-01-31 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
2019-09-05 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
2019-07-15 | 업그레이드 | Goldman | Sell → Neutral |
2019-05-31 | 개시 | H.C. Wainwright | Neutral |
2019-05-01 | 다운그레이드 | Citigroup | Buy → Neutral |
2018-12-19 | 다운그레이드 | Goldman | Neutral → Sell |
2018-12-14 | 개시 | Wolfe Research | Underperform |
2018-12-13 | 다운그레이드 | Credit Suisse | Outperform → Underperform |
2018-11-05 | 개시 | Piper Jaffray | Neutral |
2018-08-07 | 개시 | Stifel | Hold |
2018-06-21 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
2018-06-06 | 개시 | B. Riley FBR, Inc. | Buy |
2018-05-16 | 업그레이드 | Citigroup | Neutral → Buy |
2018-05-11 | 개시 | BofA/Merrill | Buy |
모두보기
Alkermes Plc 주식(ALKS)의 최신 뉴스
Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 48% Undervaluation? - simplywall.st
Where are the Opportunities in (ALKS) - news.stocktradersdaily.com
Alkermes (ALKS) to Present New Findings on ALKS 2680 at SLEEP 20 - GuruFocus
Alkermes (ALKS) to Present New Findings on ALKS 2680 at SLEEP 2025 | ALKS Stock News - GuruFocus
Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025 - PR Newswire
Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga
This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Needham Initiates Alkermes Public at Buy With $45 Price Target - marketscreener.com
Needham's Positive Outlook on Alkermes (ALKS) with Promising Sal - GuruFocus
Needham Initiates Coverage on Alkermes (ALKS) with Buy Rating | ALKS Stock News - GuruFocus
Needham's Positive Outlook on Alkermes (ALKS) with Promising Sales Projections | ALKS Stock News - GuruFocus
Controlled Release Drug Delivery Market Generated - openPR.com
Alkermes Shareholders Approve Amendments at Annual Meeting - TipRanks
(ALKS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Alkermes price target raised to $35 from $34 at BofA - MSN
Nanotechnology Drug Delivery Market Generated Opportunities, - openPR.com
Stifel maintains Alkermes stock Buy rating, $42 target By Investing.com - Investing.com Nigeria
Drug Addiction Treatment Market Projected To Witness Massive - openPR.com
Drug Abuse Treatment Market Grows Amid Rising Substance Abuse - openPR.com
Cantor Fitzgerald maintains $43 target on Alkermes stock By Investing.com - Investing.com Nigeria
Controlled Release Drug Delivery Market is in trends - openPR.com
Alkermes plc Earnings Call Highlights Growth and R&D Progress - MSN
When the Price of (ALKS) Talks, People Listen - news.stocktradersdaily.com
Alkermes plc (ALKS): Among Billionaire Jim Simons’ RenTech’s Small-Cap Stock Picks with Huge Upside Potential - Insider Monkey
Alkermes plc (NASDAQ:ALKS) Q1 2025 Earnings Call Transcript - Insider Monkey
Alkermes has near-term catalyst with narcolepsy data, says H.C. Wainwright - TipRanks
BlackRock, Inc. Reduces Stake in Alkermes PLC: A Detailed Analysis - GuruFocus
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm - ACCESS Newswire
RBC Capital Raises Price Target for Alkermes (ALKS) to $40 | ALKS Stock News - GuruFocus
Alkermes' Q1 Earnings and Revenues Fall Short of Estimates - Nasdaq
Alkermes (ALKS) Reaffirms 2025 Financial Outlook and Awaits Key Trial Results | ALKS Stock News - GuruFocus
Alkermes (ALKS) Price Target Raised to $41 by Baird Analyst | AL - GuruFocus
Alkermes (ALKS) Price Target Raised to $41 by Baird Analyst | ALKS Stock News - GuruFocus
Baird Increases Price Target for Alkermes (ALKS) on Promising Ou - GuruFocus
Baird Increases Price Target for Alkermes (ALKS) on Promising Outlook | ALKS Stock News - GuruFocus
RBC Raises Price Target on Alkermes to $40 From $39, Keeps Sector Perform Rating - marketscreener.com
Alkermes PLC (ALKS) Q1 2025 Earnings Call Highlights: Strong Proprietary Product Growth and ... - Yahoo
Alkermes PLC (ALKS) Q1 2025 Earnings Call Highlights: Strong Pro - GuruFocus
Alkermes: Q1 Earnings Snapshot - MySA
Alkermes plc Reports Q1 2025 Financial Results - TipRanks
Alkermes Plc earnings missed by $0.18, revenue fell short of estimates - Investing.com South Africa
Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible (NASDAQ:ALKS) - Seeking Alpha
Chondrosarcoma Market: Epidemiology, Therapies, Companies, - openPR.com
Alkermes to Report First Quarter Financial Results on May 1, 2025 - PR Newswire UK
Alkermes Q1 2025 Earnings Call Transcript - MarketBeat
Here's What Key Metrics Tell Us About Alkermes (ALKS) Q1 Earnings - Yahoo Finance
Alkermes Q1 Earnings, Revenue Decline - marketscreener.com
Alkermes Plc reports results for the quarter ended March 31Earnings Summary - TradingView
Alkermes PLC Q1 2025 Earnings: EPS of $0.13 Beats Estimate, Reve - GuruFocus
Alkermes (ALKS) Misses Q1 Earnings and Revenue Estimates - Yahoo Finance
Alkermes (ALKS) Exceeds Q1 Revenue Expectations and Advances Ore - GuruFocus
Alkermes Plc (ALKS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):